Allied Market Research


Gastrointestinal Cancer Drugs Market

Gastrointestinal Cancer Drugs Market Size, Share, Competitive Landscape and Trend Analysis Report, by Therapy, by Application and, by End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

Gastrointestinal cancer is the abnormal condition of the gastrointestinal tract and associated organs of digestive system, which comprises esophagus, stomach, pancreas, biliary system, small intestine, large intestine, rectum, and anus. The symptoms of gastrointestinal cancer depend on the affected organ, and include obstruction (resulting in difficulty to swallow or excrete), unusual bleeding, or other related problems.

The global gastrointestinal cancer drugs market is driven by growth in prevalence of gastrointestinal cancer, increase in demand for targeted drug delivery, rise in public awareness, government initiatives to eliminate cancer, and patent expiry of key cancer drugs. However, high cost of drug development, threat of failure, and adverse effects of cancer drug therapy, particularly chemotherapy hinder the market growth. Nevertheless, advancements in cancer drug research, such as biological/targeted therapies and personalized medicines provide opportunities for the market players to develop cancer drugs.

The global gastrointestinal cancer drug market is segmented on the basis of therapy, application, end user, and geography. Based on therapy, it is classified into immunotherapy, chemotherapy, targeted therapy, hormone therapy, adjuvant chemotherapy, and radiation therapy. On the basis application, it is divided into oncology, and radiology. Based on end user, it is categorized into hospitals, specialized cancer treatment centers, clinics, and ambulatory surgical centers. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key market players profiled in this report include Amgen Limited & Amgen Ireland Limited, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Johnson & Johnson Private Limited, GlaxoSmithKline plc., Celgene Corporation, Pfizer Inc., Sanofi, and Novartis AG.

Key Benefits

  • The report presents the market analysis of the global gastrointestinal cancer drugs market along with the regional trend and future estimations.
  • It provides extensive information about the market segments to understand the market dynamics.
  • The key factors that drive, hamper, or provide opportunities to the market are provided in the report
  • Competitive landscape of the industry along with the profile analysis of market players is provided in the report.

Gastrointestinal Cancer Drugs Market Report Highlights

Aspects Details
By Therapy
  • Immunotherapy
  • Chemotherapy
  • Targeted Therapy
  • Hormone Therapy
  • Adjuvant Chemotherapy
  • Radiation Therapy
  • Others
By Application
  • Oncology
  • Radiology
  • Others
By End User
  • Hospitals
  • Specialized Cancer Treatment Centers
  • Clinics
  • Ambulatory Surgical Centers
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players

Novartis AG, F. Hoffmann-La Roche Ltd., Johnson & Johnson Private Limited, Eli Lilly and Company, Celgene Corporation, Bristol-Myers Squibb Company, Pfizer Inc., Amgen Limited & Amgen Ireland Limited, GlaxoSmithKline plc., Sanofi

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Gastrointestinal Cancer Drugs Market

Global Opportunity Analysis and Industry Forecast, 2023-2032